InterCure Ltd. (NASDAQ:INCR) Short Interest Down 67.9% in June

InterCure Ltd. (NASDAQ:INCR) was the target of a large decline in short interest in June. As of June 30th, there was short interest totaling 15,144 shares, a decline of 67.9% from the June 15th total of 47,234 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average trading volume of 104,980 shares, the days-to-cover ratio is currently 0.1 days.

InterCure Trading Down 1.0%

INCR stock traded down $0.01 during midday trading on Friday, hitting $0.97. The stock had a trading volume of 3,609 shares, compared to its average volume of 93,334. The company’s 50-day moving average price is $0.95 and its 200 day moving average price is $0.90. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.48 and a quick ratio of 0.97. The firm has a market cap of $53.04 million, a PE ratio of 32.33 and a beta of 1.39. InterCure has a 12-month low of $0.68 and a 12-month high of $1.77.

InterCure (NASDAQ:INCR) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($0.10) earnings per share for the quarter. The business had revenue of $23.15 million during the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded InterCure from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

About InterCure

InterCure Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health.

Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives.